-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) Last Week's 31% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake
JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) Last Week's 31% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake
Every investor in JW (Cayman) Therapeutics Co. Ltd (HKG:2126) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with 56% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
And last week, individual investors endured the biggest losses as the stock fell by 31%.
Let's delve deeper into each type of owner of JW (Cayman) Therapeutics, beginning with the chart below.
See our latest analysis for JW (Cayman) Therapeutics
SEHK:2126 Ownership Breakdown September 5th 2022What Does The Institutional Ownership Tell Us About JW (Cayman) Therapeutics?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
JW (Cayman) Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at JW (Cayman) Therapeutics' earnings history below. Of course, the future is what really matters.
SEHK:2126 Earnings and Revenue Growth September 5th 2022JW (Cayman) Therapeutics is not owned by hedge funds. Bristol-Myers Squibb Company is currently the largest shareholder, with 17% of shares outstanding. For context, the second largest shareholder holds about 11% of the shares outstanding, followed by an ownership of 5.1% by the third-largest shareholder. Yiping Li, who is the third-largest shareholder, also happens to hold the title of Chairman of the Board.
Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of JW (Cayman) Therapeutics
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Shareholders would probably be interested to learn that insiders own shares in JW (Cayman) Therapeutics Co. Ltd. It has a market capitalization of just HK$1.8b, and insiders have HK$119m worth of shares, in their own names. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.
General Public Ownership
The general public -- including retail investors -- own 56% of JW (Cayman) Therapeutics. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability.
Private Company Ownership
Our data indicates that Private Companies hold 11%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Public Company Ownership
We can see that public companies hold 21% of the JW (Cayman) Therapeutics shares on issue. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand JW (Cayman) Therapeutics better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for JW (Cayman) Therapeutics you should be aware of.
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
JW(开曼)治疗有限公司(HKG:2126)的每一位投资者都应该知道最强大的股东群体。而持有这块蛋糕最大份额的是持有56%股权的个人投资者。换句话说,该集团将从他们对公司的投资中获得最大(或损失最大)。
上周,散户投资者遭受了最大的损失,该股下跌了31%。
让我们从下面的图表开始,更深入地研究JW(开曼)治疗公司的每一种所有者。
查看我们对JW(开曼)治疗公司的最新分析
联交所:2126拥有权分类2022年9月5日机构所有权告诉我们关于JW(开曼)治疗公司的什么?
机构通常在向自己的投资者报告时,以基准来衡量自己,因此一旦一只股票被纳入主要指数,它们往往会对这只股票变得更加热情。我们预计,大多数公司都会有一些机构登记在册,特别是在它们正在增长的情况下。
JW(开曼)治疗公司已经在股票登记处登记了机构。事实上,他们在该公司拥有可观的股份。这可以表明该公司在投资界具有一定的公信力。然而,最好警惕依赖机构投资者带来的所谓验证。他们也一样,有时也会犯错。如果多家机构同时改变对一只股票的看法,你可能会看到股价迅速下跌。因此,下面JW(开曼)治疗公司的盈利历史值得一看。当然,未来才是真正重要的。
联交所:2126盈利及收入增长2022年9月5日JW(开曼)治疗公司不属于对冲基金。百时美施贵宝公司目前是最大股东,持有17%的流通股。作为参考,第二大股东持有约11%的流通股,第三大股东持有5.1%的股份。第三大股东理想汽车也恰好持有董事长头衔。
我们的研究表明,前25名股东总共控制着公司不到一半的股份,这意味着公司的股票被广泛传播,没有占主导地位的股东。
研究机构持股是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪,也可以达到同样的效果。有很多分析师在追踪这只股票,所以他们的预测可能也是值得的。
JW(开曼)治疗公司的内部人士所有权
不同国家对内部人的定义可能略有不同,但董事会成员总是算数的。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
大多数人认为内部人持股是积极的,因为它可以表明董事会与其他股东很好地结盟。然而,在某些情况下,太多的权力集中在这个群体中。
股东们可能有兴趣知道,内部人士持有JW(开曼)治疗有限公司的股份。该公司市值仅为18亿港元,内部人士以自己的名义持有价值1.19亿港元的股票。看到内部人士进行一些投资是好事,但可能值得检查一下这些内部人士是否一直在买入。
一般公有制
普通公众--包括散户投资者--持有JW(开曼)治疗公司56%的股份。有了这样的持股量,散户投资者就可以集体在影响股东回报的决策中发挥作用,比如股息政策和董事任命。他们还可以对可能不会提高盈利能力的收购或合并行使投票权。
私营公司所有权
我们的数据显示,私营公司持有该公司11%的股份。私营公司可能是关联方。有时,内部人士通过持有一家私人公司来对上市公司感兴趣,而不是以个人身份。虽然很难得出任何大致的中风结论,但值得注意的是,这是一个值得进一步研究的领域。
上市公司所有权
我们可以看到,上市公司持有JW(开曼)治疗公司已发行股票的21%。很难说肯定,但这表明他们的商业利益交织在一起。这可能是一个战略利害关系,因此值得关注这一所有权变化的空间。
接下来的步骤:
拥有一家公司股票的不同集团总是值得考虑的。但为了更好地了解JW(开曼)治疗,我们需要考虑许多其他因素。一个恰当的例子:我们发现了JW(开曼)治疗公司的3个警告标志你应该意识到。
如果你更愿意了解分析师对未来增长的预测,请不要错过这一预期免费关于分析师预测的报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧